<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04524949</url>
  </required_header>
  <id_info>
    <org_study_id>IMCY-T1D-003</org_study_id>
    <secondary_id>2020-001317-20</secondary_id>
    <nct_id>NCT04524949</nct_id>
  </id_info>
  <brief_title>IMCY-0098 Proof of ACtion in Type 1 Diabetes (IMPACT Study)</brief_title>
  <acronym>IMPACT</acronym>
  <official_title>A Phase IIa, Randomized, Double-blind Placebo-controlled, Dose Comparison, Multi-centre Adaptive Design Clinical Trial to Evaluate the Immune Signature of the Treatment With the Imotope IMCY-0098 and Its Effect on the Preservation of Beta-cell Function in Adult Patients With a Recent Onset Type 1 Diabetes</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Imcyse SA</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Imcyse SA</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The IMPACT study is a study to test a new experimental drug, IMCY-0098, for the treatment of&#xD;
      type 1 diabetes (T1D).&#xD;
&#xD;
      In most people with type 1 diabetes, the pancreas loses its ability to make insulin because&#xD;
      some cells of the body's own immune system mistakenly attack and destroy the cells in the&#xD;
      pancreas that produce insulin (islet beta-cells).&#xD;
&#xD;
      The study drug IMCY-0098 is being developed to stop the body's own immune system attacking&#xD;
      and destroying the insulin-producing cells. When injected, it will induce new immune cells&#xD;
      that will specifically destroy the bad immune cells responsible for the damage to the&#xD;
      pancreas.&#xD;
&#xD;
      IMCY-0098 has previously been tested on recently diagnosed type 1 diabetes patients in the&#xD;
      first clinical study between 2017 and 2019 to collect information on the safety of IMCY-0098.&#xD;
      The next step is to test the best dose and the best number of injections that show the drug&#xD;
      can give a benefit. Two doses of IMCY-0098 will be tested and they will be compared to a&#xD;
      placebo. Safety information will also be collected during the study for all the participants.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 29, 2020</start_date>
  <completion_date type="Anticipated">April 2023</completion_date>
  <primary_completion_date type="Anticipated">April 2023</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Difference in Dried Blood Spots (DBS) fasted C-peptide between treatment and placebo groups</measure>
    <time_frame>Up to 48 weeks</time_frame>
    <description>DBS C-peptide measurements</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Changes in stimulated C-peptide response during the first two hours of a mixed meal tolerance test (MMTT)</measure>
    <time_frame>Up to 48 weeks</time_frame>
    <description>The area under the stimulated C-peptide response curve over the first two hours of a MMTT</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in DBS C-peptide measurements at each visit comparing each dose with placebo</measure>
    <time_frame>Up to 48 weeks</time_frame>
    <description>The DBS C-peptide responses at each visit</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To determine the effects of the two doses of IMCY-0098 on HbA1c</measure>
    <time_frame>Up to 48 weeks</time_frame>
    <description>Measured by change from baseline in HbA1c</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To determine the effects of the two doses of IMCY-0098 on insulin use</measure>
    <time_frame>Up to 48 weeks</time_frame>
    <description>Measured by change from baseline in insulin requirements as the total daily dose</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To determine the effects of the two doses of IMCY-0098 on glycaemia</measure>
    <time_frame>Up to 48 weeks</time_frame>
    <description>Measured by change from in Time in Range from continuous glucose monitoring compared to reference period</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To determine the effects of the two doses of IMCY 0098 on hypoglycaemia and diabetic ketoacidosis events</measure>
    <time_frame>Up to 48 weeks</time_frame>
    <description>Number of treatment-emergent severe hypoglycaemic episodes and episodes of diabetic ketoacidosis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Impact of IMCY-0098 on autoantibodies against GAD65, Islet Antigen 2 (IA 2), ZnT8 and insulin over time</measure>
    <time_frame>Up to 48 weeks</time_frame>
    <description>Change in T1D associated autoantibodies</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To evaluate the safety features of IMCY-0098 during treatment period</measure>
    <time_frame>Up to 7 days after the last dose</time_frame>
    <description>Occurrence, intensity and relationship of any listed injection site and systemic AEs during a 7-day follow-up period after each dose</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To evaluate the safety features of IMCY-0098 during the whole study duration</measure>
    <time_frame>Up to 48 weeks</time_frame>
    <description>Occurrence, intensity and relationship of any unlisted injection site and systemic AEs and occurrence and relationship of all SAEs and abnormality in physical examination, vital signs, 12-lead ECG</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To evaluate the safety features of IMCY-0098 on lymphocytes ratio</measure>
    <time_frame>Up to 48 weeks</time_frame>
    <description>Measure of CD4+/CD8+ lymphocytes ratio</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">84</enrollment>
  <condition>Diabetes Mellitus, Type 1</condition>
  <arm_group>
    <arm_group_label>IMCY-0098, low dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The dose A (Cohort 1) will consist of subcutaneous administrations of 450 µg of the peptide in two separate injections of 225 µg each (500 µL each).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>IMCY-0098, high dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The dose B (Cohort 2) will consist of subcutaneous administrations of 1350 µg of the peptide in two separate injections of 675 µg each (500 µL each).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants randomized to placebo will receive subcutaneous administrations of identical volumes of placebo solution to maintain study blind.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>IMCY-0098 450 μg</intervention_name>
    <description>Small synthetic peptide for SC admin. Solvent: alum hydroxide</description>
    <arm_group_label>IMCY-0098, low dose</arm_group_label>
    <other_name>Imotope</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>IMCY-0098 1350 μg</intervention_name>
    <description>Small synthetic peptide for SC admin. Solvent: alum hydroxide</description>
    <arm_group_label>IMCY-0098, high dose</arm_group_label>
    <other_name>Imotope</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Solvent: alum hydroxide</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Have given written informed consent.&#xD;
&#xD;
          2. Participants aged ≥ 18 years and &lt; 45 years at the time of consent&#xD;
&#xD;
          3. Have a diagnosis of T1D within maximum 9 weeks at screening (date of the first insulin&#xD;
             injection)&#xD;
&#xD;
          4. Must have at least one or more diabetes-related autoantibodies present at screening&#xD;
             (GAD65, IA-2, or ZnT8)&#xD;
&#xD;
          5. Must have random C-peptide levels ≥ 200 pmol/L measured at screening&#xD;
&#xD;
          6. Must be Human Leukocyte Antigen (HLA) DR4 positive for the main study&#xD;
&#xD;
               -  Up to 24 participants with an HLA DR4 negative status but HLA DR3 positive will&#xD;
                  be eligible for the substudy&#xD;
&#xD;
          7. Be willing to comply with intensive diabetes management&#xD;
&#xD;
          8. Be treated with insulin therapy in accordance with the local standard of care&#xD;
&#xD;
          9. Males with reproductive potential must agree to use adequate contraception up to 90&#xD;
             days after the completion of the last treatment. This includes:&#xD;
&#xD;
               -  Barrier contraception (condom and spermicide) or&#xD;
&#xD;
               -  True abstinence (where this is in accordance with the participants preferred and&#xD;
                  usual lifestyle)&#xD;
&#xD;
         10. All females must have a negative serum pregnancy test at screening. Women sexually&#xD;
             active and of childbearing potential must agree to use a highly effective&#xD;
             contraception method from screening up to 90 days after last treatment with the&#xD;
             investigational product&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Clinically significant abnormal full blood count (FBC), renal function or liver&#xD;
             function at screening including&#xD;
&#xD;
             1.1. Be immunodeficient or have any clinically significant chronic lymphopenia:&#xD;
             Leukopenia (&lt; 3,000 leukocytes /μL), neutropenia (&lt;1,500 neutrophils/μL), lymphopenia&#xD;
             (&lt;800 lymphocytes/μL), or thrombocytopenia (&lt;100,000 platelets/μL)&#xD;
&#xD;
             1.2. Evidence of renal dysfunction with creatinine greater than 1.5 times the upper&#xD;
             limit of normal&#xD;
&#xD;
             1.3. Evidence of liver dysfunction with aspartate aminotransferase (AST) or alanine&#xD;
             transaminase (ALT) greater than 3 times the upper limits of normal. Participants with&#xD;
             elevated unconjugated bilirubin (Gilbert's syndrome) are eligible if bilirubin is ≤ 3&#xD;
             times the upper limits of normal and hepatic enzymes and function are otherwise normal&#xD;
             (AST/ALT/Alkaline phosphatase within ULN), and there is no evidence of hemolysis.&#xD;
&#xD;
          2. Have signs or symptoms of serious active infection requiring IV antibiotics and/or&#xD;
             hospitalization at study entry&#xD;
&#xD;
          3. Have signs or symptoms of active COVID infection or a positive COVID PCR test during&#xD;
             the screening period&#xD;
&#xD;
          4. Have received any live attenuated vaccine within 3 months prior to the first planned&#xD;
             administration of the study product (which includes, but is not limited to: oral&#xD;
             poliomyelitis vaccine, measles-mumps-rubella vaccine, yellow fever vaccine, Japanese&#xD;
             encephalitis vaccine, dengue vaccine, rotavirus vaccine, varicella vaccine,&#xD;
             live-attenuated zoster vaccine, Bacillus Calmette-Guérin [BCG] vaccine, oral typhoid&#xD;
             vaccine)&#xD;
&#xD;
          5. Be currently pregnant or lactating, or anticipate getting pregnant until at least 24&#xD;
             weeks after last study drug administration&#xD;
&#xD;
          6. Require the use of immunosuppressive agents including chronic use of systemic&#xD;
             steroids. Topical, inhalational or intranasal corticosteroids are allowed&#xD;
&#xD;
          7. Have evidence of current or past human immunodeficiency virus (HIV), Hepatitis B or&#xD;
             Hepatitis C infection&#xD;
&#xD;
          8. Presence of any uncontrolled disease (including uncontrolled autoimmune disease) or&#xD;
             abnormal clinical laboratory results that may interfere with study conduct as judged&#xD;
             by the investigator&#xD;
&#xD;
          9. History of, or current malignancy (except excised basal cell skin cancer)&#xD;
&#xD;
         10. Current or ongoing use of non-insulin pharmaceuticals that affect glycaemic control&#xD;
             within 7 days prior to screening visit&#xD;
&#xD;
         11. Active participation in another T1D treatment study or any investigational&#xD;
             intervention study in the previous 30 days&#xD;
&#xD;
         12. Known hypersensitivity to any component of the drug product&#xD;
&#xD;
         13. CRO or Sponsor employees or employees under the direct supervision of the Investigator&#xD;
             and/or involved directly in the study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>44 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jean Van Rampelbergh</last_name>
    <role>Study Director</role>
    <affiliation>Imcyse SA</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Imcyse SA</last_name>
    <phone>+32 (0)479 98 64 64</phone>
    <email>clinical@imcyse.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Université Libre de Bruxelles - Hôpital Erasme - ULB</name>
      <address>
        <city>Brussels</city>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>UZ Brussels</name>
      <address>
        <city>Brussels</city>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Katholieke Universiteit Leuven UZ Gasthuisberg</name>
      <address>
        <city>Leuven</city>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Ospedale San Raffaele S.r.l.</name>
      <address>
        <city>Milan</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital of Lithuanian University of Health Sciences Kauno Klinikos</name>
      <address>
        <city>Kaunas</city>
        <country>Lithuania</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Klaipeda university hospital</name>
      <address>
        <city>Klaipeda</city>
        <country>Lithuania</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Vilnius university hospital Santaros klinikos</name>
      <address>
        <city>Vilnius</city>
        <country>Lithuania</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>UMC - University Children's Hospital</name>
      <address>
        <city>Ljubljana</city>
        <country>Slovenia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Department of clinical sciences, CRC/Malmö, Lund University</name>
      <address>
        <city>Lund</city>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Addenbrooke's Hospital</name>
      <address>
        <city>Cambridge</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>University Hospital of Wales</name>
      <address>
        <city>Cardiff</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Royal Infirmary of Edinburgh</name>
      <address>
        <city>Edinburgh</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Royal Devon and Exeter Hospital</name>
      <address>
        <city>Exeter</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>St James´s University Hospital</name>
      <address>
        <city>Leeds</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Leicester General Hospital</name>
      <address>
        <city>Leicester</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Guy's and St Thomas' Hospital</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Royal London Hospital</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>St George's Hospital</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Royal Victoria Infirmary</name>
      <address>
        <city>Newcastle</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Churchill Hospital</name>
      <address>
        <city>Oxford</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>Italy</country>
    <country>Lithuania</country>
    <country>Slovenia</country>
    <country>Sweden</country>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>August 11, 2020</study_first_submitted>
  <study_first_submitted_qc>August 21, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">August 24, 2020</study_first_posted>
  <last_update_submitted>November 2, 2021</last_update_submitted>
  <last_update_submitted_qc>November 2, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 3, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Diabetes Mellitus Type 1</keyword>
  <keyword>Autoimmune disease</keyword>
  <keyword>Immunotherapy</keyword>
  <keyword>Diabetes treatment</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 1</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

